JP2021526818A - 心筋症のためのaav心臓遺伝子治療 - Google Patents
心筋症のためのaav心臓遺伝子治療 Download PDFInfo
- Publication number
- JP2021526818A JP2021526818A JP2020568431A JP2020568431A JP2021526818A JP 2021526818 A JP2021526818 A JP 2021526818A JP 2020568431 A JP2020568431 A JP 2020568431A JP 2020568431 A JP2020568431 A JP 2020568431A JP 2021526818 A JP2021526818 A JP 2021526818A
- Authority
- JP
- Japan
- Prior art keywords
- raav
- heart
- gene
- aav
- cardiac
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000747 cardiac effect Effects 0.000 title claims abstract description 46
- 208000031229 Cardiomyopathies Diseases 0.000 title claims description 20
- 238000001415 gene therapy Methods 0.000 title description 10
- 108700019146 Transgenes Proteins 0.000 claims abstract description 97
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 78
- 239000000203 mixture Substances 0.000 claims abstract description 52
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 49
- 238000000034 method Methods 0.000 claims abstract description 48
- 229940088872 Apoptosis inhibitor Drugs 0.000 claims abstract description 20
- 239000000158 apoptosis inhibitor Substances 0.000 claims abstract description 20
- 239000002245 particle Substances 0.000 claims description 57
- 239000013608 rAAV vector Substances 0.000 claims description 52
- 102100023097 Protein S100-A1 Human genes 0.000 claims description 42
- 101710156967 Protein S100-A1 Proteins 0.000 claims description 42
- 206010019280 Heart failures Diseases 0.000 claims description 35
- 206010056370 Congestive cardiomyopathy Diseases 0.000 claims description 32
- 201000010046 Dilated cardiomyopathy Diseases 0.000 claims description 32
- 150000007523 nucleic acids Chemical class 0.000 claims description 31
- 239000013598 vector Substances 0.000 claims description 30
- 108020004707 nucleic acids Proteins 0.000 claims description 28
- 102000039446 nucleic acids Human genes 0.000 claims description 28
- 208000019622 heart disease Diseases 0.000 claims description 27
- 230000014509 gene expression Effects 0.000 claims description 26
- 230000006907 apoptotic process Effects 0.000 claims description 20
- 210000000234 capsid Anatomy 0.000 claims description 17
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims description 15
- 241000972680 Adeno-associated virus - 6 Species 0.000 claims description 15
- 238000002347 injection Methods 0.000 claims description 15
- 239000007924 injection Substances 0.000 claims description 15
- 241000702421 Dependoparvovirus Species 0.000 claims description 14
- 230000002441 reversible effect Effects 0.000 claims description 14
- 230000008488 polyadenylation Effects 0.000 claims description 13
- 241000894007 species Species 0.000 claims description 12
- 108090000565 Capsid Proteins Proteins 0.000 claims description 11
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 11
- 241001465754 Metazoa Species 0.000 claims description 11
- 241000202702 Adeno-associated virus - 3 Species 0.000 claims description 8
- 102000021350 Caspase recruitment domains Human genes 0.000 claims description 8
- 108091011189 Caspase recruitment domains Proteins 0.000 claims description 8
- 210000002027 skeletal muscle Anatomy 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 7
- 230000002107 myocardial effect Effects 0.000 claims description 7
- 108010085238 Actins Proteins 0.000 claims description 6
- 241001164825 Adeno-associated virus - 8 Species 0.000 claims description 6
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 claims description 6
- 102000004987 Troponin T Human genes 0.000 claims description 4
- 108090001108 Troponin T Proteins 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- 208000028867 ischemia Diseases 0.000 claims description 4
- 239000002502 liposome Substances 0.000 claims description 4
- 102000007469 Actins Human genes 0.000 claims description 3
- 241001655883 Adeno-associated virus - 1 Species 0.000 claims description 3
- 101710086403 Carbonic anhydrase-related protein Proteins 0.000 claims description 3
- 108090000362 Lymphotoxin-beta Proteins 0.000 claims description 3
- 108010067385 Myosin Light Chains Proteins 0.000 claims description 3
- 102000016349 Myosin Light Chains Human genes 0.000 claims description 3
- 101710098224 Myosin regulatory light chain 2, atrial isoform Proteins 0.000 claims description 3
- 101710105127 Myosin regulatory light chain 2, ventricular/cardiac muscle isoform Proteins 0.000 claims description 3
- 102000013534 Troponin C Human genes 0.000 claims description 3
- 102100036859 Troponin I, cardiac muscle Human genes 0.000 claims description 3
- 101710128251 Troponin I, cardiac muscle Proteins 0.000 claims description 3
- 108010051583 Ventricular Myosins Proteins 0.000 claims description 3
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 claims description 3
- 229960004373 acetylcholine Drugs 0.000 claims description 3
- 230000003551 muscarinic effect Effects 0.000 claims description 2
- 238000011282 treatment Methods 0.000 abstract description 51
- 230000008901 benefit Effects 0.000 abstract description 7
- 230000002195 synergetic effect Effects 0.000 abstract description 5
- 239000013607 AAV vector Substances 0.000 abstract description 4
- 230000008685 targeting Effects 0.000 abstract description 4
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 241000282472 Canis lupus familiaris Species 0.000 description 50
- 235000018102 proteins Nutrition 0.000 description 43
- 239000011575 calcium Substances 0.000 description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 20
- 229910052791 calcium Inorganic materials 0.000 description 20
- 238000002360 preparation method Methods 0.000 description 19
- 201000010099 disease Diseases 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 16
- 230000001225 therapeutic effect Effects 0.000 description 15
- 206010007559 Cardiac failure congestive Diseases 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 12
- 230000001640 apoptogenic effect Effects 0.000 description 11
- 210000004413 cardiac myocyte Anatomy 0.000 description 11
- 239000002299 complementary DNA Substances 0.000 description 11
- 238000001476 gene delivery Methods 0.000 description 11
- 238000013459 approach Methods 0.000 description 10
- 108020004999 messenger RNA Proteins 0.000 description 10
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 9
- 230000002438 mitochondrial effect Effects 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 230000004064 dysfunction Effects 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 238000012384 transportation and delivery Methods 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- 241000282465 Canis Species 0.000 description 6
- 102000004420 Creatine Kinase Human genes 0.000 description 6
- 108010042126 Creatine kinase Proteins 0.000 description 6
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000004217 heart function Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000010606 normalization Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 5
- 102000011727 Caspases Human genes 0.000 description 5
- 108010076667 Caspases Proteins 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000004898 mitochondrial function Effects 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 239000013646 rAAV2 vector Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 230000002861 ventricular Effects 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 102000001039 Dystrophin Human genes 0.000 description 4
- 108010069091 Dystrophin Proteins 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000003414 extremity Anatomy 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000002595 magnetic resonance imaging Methods 0.000 description 4
- 238000007726 management method Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000013184 cardiac magnetic resonance imaging Methods 0.000 description 3
- 230000008828 contractile function Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000003205 diastolic effect Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 235000021472 generally recognized as safe Nutrition 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 201000006938 muscular dystrophy Diseases 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 210000001908 sarcoplasmic reticulum Anatomy 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108010052500 Calgranulin A Proteins 0.000 description 2
- 108010052495 Calgranulin B Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101000693049 Homo sapiens Protein S100-A14 Proteins 0.000 description 2
- 101000727775 Homo sapiens Protein S100-A7A Proteins 0.000 description 2
- 101000821885 Homo sapiens Protein S100-B Proteins 0.000 description 2
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 208000029549 Muscle injury Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 108700005081 Overlapping Genes Proteins 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 108091036407 Polyadenylation Proteins 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 102100030102 Protein S100-A7A Human genes 0.000 description 2
- 102100032442 Protein S100-A8 Human genes 0.000 description 2
- 102100032420 Protein S100-A9 Human genes 0.000 description 2
- 102100021487 Protein S100-B Human genes 0.000 description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- 102000058242 S100A12 Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 229960001456 adenosine triphosphate Drugs 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 238000003782 apoptosis assay Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000028956 calcium-mediated signaling Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N ***e Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000002064 heart cell Anatomy 0.000 description 2
- VRLIPUYDFBXWCH-UHFFFAOYSA-N hydridocarbon(.) Chemical compound [CH] VRLIPUYDFBXWCH-UHFFFAOYSA-N 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000008141 laxative Substances 0.000 description 2
- 230000002475 laxative effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000004065 mitochondrial dysfunction Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 102000005681 phospholamban Human genes 0.000 description 2
- 108010059929 phospholamban Proteins 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000005522 programmed cell death Effects 0.000 description 2
- 230000004853 protein function Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 102100026656 Actin, alpha skeletal muscle Human genes 0.000 description 1
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 1
- 241001164823 Adeno-associated virus - 7 Species 0.000 description 1
- 241000649045 Adeno-associated virus 10 Species 0.000 description 1
- 101100524317 Adeno-associated virus 2 (isolate Srivastava/1982) Rep40 gene Proteins 0.000 description 1
- 101100524319 Adeno-associated virus 2 (isolate Srivastava/1982) Rep52 gene Proteins 0.000 description 1
- 101100524321 Adeno-associated virus 2 (isolate Srivastava/1982) Rep68 gene Proteins 0.000 description 1
- 101100524324 Adeno-associated virus 2 (isolate Srivastava/1982) Rep78 gene Proteins 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 108090000663 Annexin A1 Proteins 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 108700000712 BH3 Interacting Domain Death Agonist Proteins 0.000 description 1
- 102000055105 BH3 Interacting Domain Death Agonist Human genes 0.000 description 1
- 108091007065 BIRCs Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000051485 Bcl-2 family Human genes 0.000 description 1
- 108700038897 Bcl-2 family Proteins 0.000 description 1
- 201000006935 Becker muscular dystrophy Diseases 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- 101150044789 Cap gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 102000004726 Connectin Human genes 0.000 description 1
- 108010002947 Connectin Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- 206010012812 Diffuse cutaneous mastocytosis Diseases 0.000 description 1
- 208000011345 Duchenne and Becker muscular dystrophy Diseases 0.000 description 1
- 102100024108 Dystrophin Human genes 0.000 description 1
- 101710175001 E1B protein, small T-antigen Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010016803 Fluid overload Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 101000834207 Homo sapiens Actin, alpha skeletal muscle Proteins 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 description 1
- 101001030243 Homo sapiens Myosin-7 Proteins 0.000 description 1
- 101000653788 Homo sapiens Protein S100-A11 Proteins 0.000 description 1
- 101000693054 Homo sapiens Protein S100-A13 Proteins 0.000 description 1
- 101000693050 Homo sapiens Protein S100-A16 Proteins 0.000 description 1
- 101000685726 Homo sapiens Protein S100-A2 Proteins 0.000 description 1
- 101000685725 Homo sapiens Protein S100-A3 Proteins 0.000 description 1
- 101000685719 Homo sapiens Protein S100-A5 Proteins 0.000 description 1
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000055031 Inhibitor of Apoptosis Proteins Human genes 0.000 description 1
- 102000001483 Initiator Caspases Human genes 0.000 description 1
- 108010054031 Initiator Caspases Proteins 0.000 description 1
- 108091027974 Mature messenger RNA Proteins 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 208000011682 Mitral valve disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 208000021908 Myocardial disease Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 102100038934 Myosin-7 Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101100007739 Neosartorya fumigata (strain ATCC MYA-4609 / Af293 / CBS 101355 / FGSC A1100) crmA gene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 102100029796 Protein S100-A10 Human genes 0.000 description 1
- 102100029811 Protein S100-A11 Human genes 0.000 description 1
- 101710110949 Protein S100-A12 Proteins 0.000 description 1
- 102100025670 Protein S100-A13 Human genes 0.000 description 1
- 102100026298 Protein S100-A14 Human genes 0.000 description 1
- 102100026296 Protein S100-A16 Human genes 0.000 description 1
- 102100023089 Protein S100-A2 Human genes 0.000 description 1
- 102100023090 Protein S100-A3 Human genes 0.000 description 1
- 102100023088 Protein S100-A5 Human genes 0.000 description 1
- 102100021494 Protein S100-P Human genes 0.000 description 1
- 102100023107 Protein S100-Z Human genes 0.000 description 1
- 102000015176 Proton-Translocating ATPases Human genes 0.000 description 1
- 108010039518 Proton-Translocating ATPases Proteins 0.000 description 1
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 102000019027 Ryanodine Receptor Calcium Release Channel Human genes 0.000 description 1
- 108010012219 Ryanodine Receptor Calcium Release Channel Proteins 0.000 description 1
- 108010005260 S100 Calcium Binding Protein A6 Proteins 0.000 description 1
- 102000005881 S100 Calcium Binding Protein A6 Human genes 0.000 description 1
- 108010005256 S100 Calcium Binding Protein A7 Proteins 0.000 description 1
- 102000005871 S100 Calcium Binding Protein A7 Human genes 0.000 description 1
- 108010085149 S100 Calcium-Binding Protein A4 Proteins 0.000 description 1
- 102000007460 S100 Calcium-Binding Protein A4 Human genes 0.000 description 1
- 108010015695 S100 calcium binding protein A10 Proteins 0.000 description 1
- 108700031547 S100A1 Proteins 0.000 description 1
- 108700016890 S100A12 Proteins 0.000 description 1
- 101150097337 S100A12 gene Proteins 0.000 description 1
- 102100027732 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 Human genes 0.000 description 1
- 101710109123 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 238000012338 Therapeutic targeting Methods 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 208000033774 Ventricular Remodeling Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000037147 athletic performance Effects 0.000 description 1
- 108700000711 bcl-X Proteins 0.000 description 1
- 102000055104 bcl-X Human genes 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 230000010428 chromatin condensation Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960003920 ***e Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000001541 differential confocal microscopy Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 238000011833 dog model Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 208000036260 idiopathic disease Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- -1 initiation sites Proteins 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 230000010016 myocardial function Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 230000025308 nuclear transport Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229960002164 pimobendan Drugs 0.000 description 1
- GLBJJMFZWDBELO-UHFFFAOYSA-N pimobendane Chemical compound C1=CC(OC)=CC=C1C1=NC2=CC=C(C=3C(CC(=O)NN=3)C)C=C2N1 GLBJJMFZWDBELO-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 101150066583 rep gene Proteins 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 210000002235 sarcomere Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 208000021510 thyroid gland disease Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 210000005243 upper chamber Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0375—Animal model for cardiovascular diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Marine Sciences & Fisheries (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
本出願は、2018年6月8日に出願された米国仮出願第 62/682,772号および2019年3月21に出願された米国仮出願第 62/822,015号の出願日の利益を主張し、これらの各々の内容全体は、参照により援用される。
拡張型心筋症(DCM)は、イヌにおける心臓疾患の第二の最も一般的な原因であり、二次的兆候の医療管理は、唯一の治療選択肢である。罹患したイヌの予後は、疾患の段階および品種に依存する。ドーベルマン・ピンシェルは、一旦うっ血性心不全(CHF)が生じると、最大の生存が6か月未満で、具体的に迅速なおよび一様な進行を示す。拡張型心筋症(DCM)は、最も一般的なタイプのヒト心筋症であり、20〜60の成年者に発生する。それは、心臓の心室および心房、夫々、心臓の下方および上方の房(chamber)に影響する。
心筋症は、対象における心臓疾患の第二の最も一般的な原因であり、および、二次的な兆候の医療管理が唯一の治療選択肢である。罹患した対象の予後は、疾患の段階および品種に依存する。心臓機能は、カルシウム依存性のシグナリングに重大に依存している。心臓疾患の間、心細胞内のカルシウムチャネルの機能障害は、カルシウム循環の異常を促進し、さらに心臓機能を阻害する。カルシウム循環の異常を低減するための遺伝子導入ストラテジーは、小および大動物モデルならびにヒト臨床試験における心疾患を寛解させることが示されている。
以下の図面は、本願明細書の一部を形成し、および、本発明のある側面をさらに示すために包含される。本開示は、似たような参照数字が似たような要素を同定する、添付の図面と併せて、以下の記載を参照することによって、より良く理解され得る。
本発明は、対象における心臓疾患、例として心筋症についての心臓遺伝子治療の組成物および方法に関する。本発明の方法は、2つの導入遺伝子の同時送達および発現のための、組換えAAV(rAAV)粒子の使用に関する。本発明の導入遺伝子は、少なくとも2つのクラスのタンパク質を含み、各々が、心臓疾患の異なる側面に取り組むための特定の機能を有する。1つのクラスの導入遺伝子は、心筋細胞におけるカルシウムシグナリングを調節する(例として、S100ファミリータンパク質)。他のクラスの導入遺伝子は、アポトーシスリプレッサーを含む。いくつかの態様において、導入遺伝子は、心臓S100カルシウム結合タンパク質A1(cS100A1)またはそのバリアント、およびカスパーゼ動員ドメインを有する心臓アポトーシスリプレッサー(cARC)またはそのバリアントであり得る。
(NCBI参照配列: XM_005622816.2)
ATGGGCTCTGAGCTGGAGACAGCGATGGAGACTCTCATCAATGTGTTCCATGCCCACTCGGGCAAGGAGGGAAACAAGTACAAGCTGAGCAAGAAGGAGCTAAAGGAGCTGCTGCAGACTGAGCTCTCCGGCTTCCTGGACGCCCAGAAGGATGCGGATGCTGTGGACAAGGTGATGAAAGAGCTAGATGAGAATGGAGATGGGGAGGTGGACTTCCAGGAGTATGTGGTGCTGGTGGCTGCCCTCACAGTGGCCTGTAACAACTTCTTCTGGGAAAACAGTTGA (配列番号1)
(NCBI参照配列: XM_003999773.3)
ATGGGCTCAGAGCTGGAGACGGCGATGGAGACTCTCATCAACGTGTTCCACGCCCACTCGGGCAAGGAGGGAGACAAGTACAAGCTGAGCAAGAAGGAGCTAAAAGAGCTGCTGCAGACCGAGCTCTCTGGCTTCCTGGACGCCCAGAAGGATGCCGACGCTGTGGACAAGGTGATGAAAGAGCTAGACGAGAATGGAGATGGGGAGGTGGACTTCCAAGAGTATGTGGTGCTGGTGGCTGCCCTCACAGTGGCCTGTAACAACTTTTTCTGGGAGAACAGTTGA (配列番号2)
cARC cDNA配列の非制限例は、以下に列挙される。
(NCBI参照配列: NM_001048121.1)
ATGCAGGAAGCGCCAGCCGCGCTGCCCACGGAGCCGGGCCCCAGCCCCGTGCCTGCCTTCCTCGGCAAGCTGTGGGCGCTGGTGGGCGACCCGGGGACCGACCACCTCATCCGCTGGAGCCCGAGCGGGACCAGTTTCCTCGTCAGCGACCAGAGCCGCTTCGCCAAGGAAGTGCTGCCCCAGTACTTCAAGCACAGCAACATGGCGAGCTTCGTGCGGCAGCTCAACATGTACGGTTTTCGGAAGGTGGTGAGCATCGAGCAGGGCGGCCTGCTCAGGCCGGAGCGCGACCACGTCGAGTTCCAGCACCCGAGCTTCGTCCGCGGCCGAGAGCAACTCCTGGAGCGCGTGCGGCGCAAGGTGCCCGCGCTGCGCAGCGACGACGGCCGCTGGCGCCCCGAGGACCTGGGCCGGCTGCTGGGCGAGGTGCAGGCTTTGCGGGGAGTGCAGGAGATCACCGAGGCGCGGCTGCGGGAGCTCAGGCAGCAGAACGAGATCTTATGGAGGGAGGTGGTGACTCTGCGGCAGAGCCACGGTCAGCAGCATCGCGTCATTGGCAAGCTGATCCAGTGCCTCTTTGGGCCACTTCAGACAGGGTCCAGCGGCGCAGGAGCTAAGAGAAAGCTGTCTCTGATGCTGGATGAGGGGAGCTCATGCCCAACACCGGCCAAATTCAACACCTGTCCTTTACCTGGTGCCCTCTTGCAGGATCCCTACTTTATCCAGTCGCCCCTCCCAGAGACCACCTTGGGCCTCAGCAGCTCTCATAGGACCAGGGGCCCTATCATCTCTGACATCCATGAAGACTCTCCCTCCCCTGATGGGACCAGGCTTTCTCCTTCCAGTGGTGGCAGGAGGGAGAAGGGCCTGGCACTGCTCAAAGAAGAGCCGGCCAGCCCAGGGGGGGAAGGCGAGGCCGGGCTGGCCCTGGCCCCAAACGAGTGTGACTTCTGCGTGACAGCCCCCCCCCCACTGTCCGTGGCTGTGGTGCAGGCCATCCTGGAAGGGAAGGGGAACTTCAGCCCCGAGGGGCCCAGGAATGCCCAACAGCCTGAACCAAGGGGTCCCAGGGAGGTACCTGACAGGGGGACTCTGGGCCTGGACAGGGGGGCACGAAGCCCAGAGAATCTGCTGCCTCCCATGCTGCTTCGGGCCCCCCCTGAAAGTGTGGAGCCTGCAGGGCCCCTGGATGTGCTGGGCCCCAGCCATCAAGGGCGAGAATGGACCCTGATGGACTTGGACATGGAGCTGTCCCTGATGCAGCCCTTGGGTCCAGAGAGGAGTGAGACTGAGCTGGCGGTCAAGGGGTTAAATTCTCCGGGGCCAGGGAAGGACTCCACACTTGGGGCACCACTCCTGCTCGATGTCCAAGCGGCTTTGGGAGGCCCAGCTCTCAGCCTTCCTGGAGCTTTAACCATTTACAGCACCCCTGAGAGCCGAGCCAACTACCTAGGCCCAGGGGCCAATCCCTCCCCCTGA (配列番号3)
(NCBI参照配列: XM_006941587.2)
ATGGGCAATGCGCAGGAGCGGCCCTCAGAGACGATCGATCGCGAGCGGAAACGCCTAGTGGAGACGCTGCAGGACGACTCCGGGCTGCTGCTGGATGCACTGCTGGCGCGCGGCGTGCTCACCGGGCCTGAGTATGAGGCGTTGGACGCGCTGCCTGATGCCGAGCGCAGGGTGCGTCGCCTGCTGCTGCTGGTACAAAGCAAGGGCGAGGCCGCCTGCCAGGAGCTGCTGCACTGCGCCCAGCGTACTACGCGCGCGCCAGACCCGGCCTGGGACTGGCAGCACGTGGGCACTGGCTACCGGGAACGCAGCTACGACTCTCCATGCCCTGGCCACTGGACGCCTGAGGCACCTGACTTGAGGACCGCTTGCCCCGAAACGCCCAGAGCTTCAGACTGCGACGAGGCTGGGGTTTCAGGGGGCTCGGAGGCAGTATCCGGAACCCTCGAGGAACTCGATCCGGAAGTGGAAGCTGAAGTCTCTGAAGGGGCTGAGCCAGAGCCAGAGCCAGAGCCCGACTTTGAGGCGGGTGATGAGTCTGAAGATTCC (配列番号4)
本発明のいくつかの側面は、心臓疾患の遺伝子治療のために使用され得る組換えAAVベクターに関する。本明細書に使用されるとき、用語「ベクター」は、核酸ベクター(例として、プラスミドまたは組換えウイルスゲノム)、野生型AAVゲノム、またはウイルスゲノムを含むウイルスを指し得る。
さらに本明細書に提供されるのは、rAAV粒子またはかかる粒子を含有するrAAV調製物である。rAAV粒子は、本明細書に記載のウイルスカプシドおよびrAAVベクターを含み、これは、ウイルスカプシドによってカプシド化される。rAAV 粒子を生成する方法は、当該技術分野において知られており、および、市販されている(例として、Zolotukhin et al., Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28 (2002) 158-167;および米国特許出願公開番号US2007/0015238およびUS2012/0322861を参照のこと、これらは参照により本明細書に組み込まれる;ならびにプラスミドおよびキットは、ATCCおよびCell Biolabs, Inc.から入手可能である)。
本発明はまた、開示されたrAAV粒子または調製物の1以上を含む組成物に関する。いくつかの態様において、rAAV調製物は、第一の血清型(例として、AAV3、AAV5、AAV6、またはAAV9)のITRを含有するrAAVベクターおよびrAAVベクターをカプシド化するカプシドタンパク質を含むrAAV粒子を含む。いくつかの態様において、カプシドタンパク質は、第一の血清型(例として、AAV3、AAV5、AAV6、またはAAV9)のものである。いくつかの態様において、調製物は、AAV2 ITRを含有するrAAVベクターを使用して調製された調製物と比較して、(例として、Huh7などのヒト肝細胞がん細胞株において)、少なくとも4倍高い形質導入効率を有する。
いくつかの側面において、本発明は、1以上の心臓状態(例として、心筋症、肥大型 心筋症、拡張型心筋症、心不全、心臓疾患、等々)を処置する際に有用な組成物および方法を提供する。いくつかの態様において、本願によって提供される組成物は、心臓への複数回の直接注射を介して、対象に提供することができる。対象に提供することができる例示のAAV構築物は、図1に描写される。ある態様において、かかる例示の構築物は、組換えAAV(例として、AAV6)によってカプシド化され、および、1以上の心臓状態(例として、心筋症)の2つの別々の側面に取り組むために、S100カルシウム結合タンパク質A1(S100A1)およびカスパーゼ動員ドメインを有するアポトーシスリプレッサー(ARC)の種特異的コード配列を含む。図1における例示的な構築物の両方の導入遺伝子は、心臓TnTプロモーターによって駆動され、およびよって心筋細胞においてのみ発現するだろう。
拡張型心筋症(DCM)は、イヌにおける後天性心臓疾患の第二の最も一般的な原因であり、最も一般的にはドーベルマン・ピンシェル、グレート・デーンおよびアイリッシュ・ウルフハウンドなどの大型犬種に影響する。この疾患に罹患したヒトにおいて、心臓移植および左心室補助デバイスなどの外科手術選択肢が存在する。しかしながら、獣医学において、唯一の治療的選択肢は、心不全に関連する兆候の医療管理である。罹患したイヌの予後は、疾患の段階および品種に依存する。例えば、ほとんどのドーベルマン・ピンシェルは、うっ血性心不全(CHF)の発症後6か月未満生存する。対照的にコッカー・スパニエルなどの他の品種は、それより長く生存する傾向がある。心臓疾患が進行するにつれて、心臓細胞内のカルシウム移動を調節するチャネルの機能障害は、カルシウム循環異常、さらに心臓の収縮および弛緩の機能障害を促進する。注目すべきことに、カルシウム輸送異常は、天然に存在するDCM5を有するイヌにおいて認識されており、および、多くの異なる病理学に続発する心不全とともに発生する。
S100A1/ARC自己相補的なベクターの心臓AAV遺伝子送達は、デュシェンヌ型筋ジストロフィー(ジストロフィン欠乏症)のマウスおよびイヌモデルにおいて査定された。以前には、AAV8(その複数のバリアントを包含する)、AAV9、およびAAVrh.10血清型は、イヌ心臓に感染するそれらの能力について比較され、およびAAVrh.10は、最も効率的であると見出された。この理由のために、AAVrh.10は、この例において記載されるすべての実験のために使用された。
2匹のドーベルマン・ピンシェル対象は、今日までに、AAVrh.10−S100A1/ARCで処置され、ここで、両方のイヌは、処置の時点で心不全を経験していた。最初のイヌは、処置の時点で死に近く、10%のみの心臓駆出率を呈した。処置後24時間以内に、駆出率は、25%まで改善した(データは示さず)。処置後4か月での、イヌの最初の経過観察訪問において、駆出率は、26%で着実に維持されていた。この対象は、処置後5か月でも依然として生存していた。
これらの予備知見に基づき、AAVrh.10−S100A1/ARC処置は、イヌにおける心臓機能を正常範囲まで回復することができる。
数個の本発明の態様が、本明細書に記載され、および、説明されているが、当業者は、本明細書に記載の、機能を実施するための、および/または、結果および/または1以上の利点を得るための、様々な他の手段および/または構造を容易に心に描くだろう。および、かかるバリエーションおよび/または改変の各々は、本明細書に記載の本発明の態様の範囲内であるとみなされる。より一般的には、当業者は、本明細書に記載のすべてのパラメータ、寸法、材料、および配置は、例示的であることを意味すること、および、実際のパラメータ、寸法、材料および/または配置は、本発明の教示が使用される特定の出願(単数または複数)に依存するだろうということを、容易に理解するだろう。
本明細書に開示の、すべての参考文献、特許および特許出願は、各々が引用される主題に関して、参考により援用され、いくつかのケースにおいて、文献全体を包含し得る。
不定冠詞「a」および「an」は、本明細書および請求項に使用されるとき、それとは反対であることが明確に表されない限り、「少なくとも1の」を意味すると理解されるべきである。
Claims (25)
- 対象の心臓に2以上の導入遺伝子を送達するための組換えアデノ随伴ウイルス(rAAV)核酸ベクターであって、該ベクターは、5’から3’の順に、第一のアデノ随伴ウイルス(AAV)逆方向末端反復(ITR)配列、2以上の導入遺伝子および2以上の導入遺伝子に操作可能に連結されたプロモーター、ポリアデニル化シグナル、および第二のAAV逆方向末端反復(ITR)配列を含み、ここで2以上の導入遺伝子は、S100ファミリータンパク質およびアポトーシスインヒビターを含む、前記組換えアデノ随伴ウイルス(rAAV)核酸ベクター。
- S100ファミリータンパク質が、心臓S100カルシウム結合タンパク質A1 (cS100A1)またはそのバリアントである、請求項1に記載のrAAVベクター。
- アポトーシスインヒビターが、カスパーゼ動員ドメインを有する心臓アポトーシスリプレッサー(cARC)またはそのバリアントである、請求項1または2に記載のrAAVベクター。
- 配列内リポソーム進入部位(IRES)が、cS100A1導入遺伝子とcARC 導入遺伝子との間に存在する、請求項2または3に記載のrAAVベクター。
- 導入遺伝子が、種特異的である、請求項1〜4のいずれか一項に記載のrAAVベクター。
- プロモーターが、心臓に限局的なプロモーターである、請求項1〜5のいずれか一項に記載のrAAVベクター。
- 心臓に限局的なプロモーターが、α−ミオシン重鎖遺伝子、6−ミオシン重鎖遺伝子、ミオシン軽鎖2v遺伝子、ミオシン軽鎖2a遺伝子、CARP遺伝子、心臓α−アクチン遺伝子、心臓m2ムスカリン性アセチルコリン遺伝子、ANF、心臓トロポニンC、心臓トロポニンI、心臓トロポニンT(cTnT)、心筋小胞体Ca−ATPアーゼ遺伝子、および骨格筋α−アクチンからなる遺伝子の群、およびMLC−2v遺伝子に由来する人工心臓プロモーターから選択される、請求項6に記載のrAAVベクター。
- 心臓に限局的なプロモーターが、cTnTである、請求項6または7に記載のrAAVベクター。
- AAVカプシド中にカプシド化された、請求項1〜8のいずれか一項に記載のrAAVベクターを含むrAAV粒子。
- AAVカプシドが、AAV1、AAV2、AAV3、AAV6、AAV8、またはAAV9血清型に由来するカプシドタンパク質を含む、請求項9に記載のrAAV粒子。
- AAVカプシドが、AAVrh.10血清型に由来するカプシドタンパク質を含む、請求項9に記載のrAAV粒子。
- 請求項9〜11のいずれか一項に記載のrAAV粒子を含む組成物。
- 請求項12に記載の組成物または請求項9〜11のいずれか一項に記載のrAAV粒子を対象に投与することを含む、心臓疾患を患う対象の処置の方法。
- 心臓疾患が、対象において心不全を引き起こすものである、請求項13に記載の方法。
- 心臓疾患が、心筋症である、請求項13または14に記載の方法。
- 心臓疾患が、肥大型心筋症または拡張型心筋症である、請求項13〜15のいずれか一項に記載の方法。
- 心臓疾患が、急性虚血である、請求項13または14に記載の方法。
- 組成物が、対象の心臓に注射を介して投与される、請求項13〜17のいずれか一項に記載の方法。
- 組成物の投与が、対象の心臓における2以上の導入遺伝子の発現を結果として生じる、請求項13〜18のいずれか一項に記載の方法。
- 対象が、哺乳動物である、請求項13〜19のいずれか一項に記載の方法。
- 哺乳動物が、ヒトである、請求項20に記載の方法。
- 哺乳動物が、伴侶動物である、請求項20に記載の方法。
- 伴侶動物が、イヌまたはネコである、請求項22に記載の方法。
- S100ファミリータンパク質を含む導入遺伝子が、アポトーシスインヒビターを含む導入遺伝子の5’側に位置する、請求項1〜8のいずれか一項に記載のrAAVベクター。
- アポトーシスインヒビターを含む導入遺伝子が、S100ファミリータンパク質を含む導入遺伝子の5’側に位置する、請求項1〜8のいずれか一項に記載のrAAVベクター。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2024062211A JP2024097779A (ja) | 2018-06-08 | 2024-04-08 | 心筋症のためのaav心臓遺伝子治療 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862682772P | 2018-06-08 | 2018-06-08 | |
US62/682,772 | 2018-06-08 | ||
US201962822015P | 2019-03-21 | 2019-03-21 | |
US62/822,015 | 2019-03-21 | ||
PCT/US2019/036157 WO2019237067A1 (en) | 2018-06-08 | 2019-06-07 | Aav cardiac gene therapy for cardiomyopathy |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2024062211A Division JP2024097779A (ja) | 2018-06-08 | 2024-04-08 | 心筋症のためのaav心臓遺伝子治療 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021526818A true JP2021526818A (ja) | 2021-10-11 |
JPWO2019237067A5 JPWO2019237067A5 (ja) | 2024-05-15 |
Family
ID=68770676
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020568431A Pending JP2021526818A (ja) | 2018-06-08 | 2019-06-07 | 心筋症のためのaav心臓遺伝子治療 |
JP2024062211A Pending JP2024097779A (ja) | 2018-06-08 | 2024-04-08 | 心筋症のためのaav心臓遺伝子治療 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2024062211A Pending JP2024097779A (ja) | 2018-06-08 | 2024-04-08 | 心筋症のためのaav心臓遺伝子治療 |
Country Status (14)
Country | Link |
---|---|
US (1) | US20210260215A1 (ja) |
EP (1) | EP3814512A4 (ja) |
JP (2) | JP2021526818A (ja) |
KR (1) | KR20210018902A (ja) |
CN (1) | CN112272705A (ja) |
AU (1) | AU2019282822A1 (ja) |
BR (1) | BR112020024935A2 (ja) |
CA (1) | CA3100280A1 (ja) |
CL (1) | CL2020003190A1 (ja) |
CO (1) | CO2020016718A2 (ja) |
IL (1) | IL279225B1 (ja) |
MX (1) | MX2020013313A (ja) |
SG (1) | SG11202011061SA (ja) |
WO (1) | WO2019237067A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11202112140SA (en) * | 2019-07-19 | 2021-11-29 | University Of Florida Research Foundation Incorporated | Aav cardiac gene therapy for cardiomyopathy in humans |
BR112023001336A2 (pt) * | 2020-08-05 | 2023-02-14 | Spacecraft Seven Llc | Terapia gênica de csrp3 (proteína 3 rica em cisteína e glicina) |
WO2022140402A1 (en) * | 2020-12-23 | 2022-06-30 | University Of Florida Research Foundation, Incorporated | Increased packaging efficiency of vector for cardiac gene therapy |
EP4239063A1 (en) * | 2022-03-02 | 2023-09-06 | CEVEC Pharmaceuticals GmbH | Improved cell lines and methods for the production of adeno-associated vectors |
WO2023166026A1 (en) * | 2022-03-02 | 2023-09-07 | Cevec Pharmaceuticals Gmbh | Improved cell lines and methods for the production of adeno-associated vectors |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016521708A (ja) * | 2013-06-07 | 2016-07-25 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 環状アデノシン一リン酸−インコンピテントアデニリルシクラーゼならびに心不全を処置するおよび心機能を増大させるための組成物および方法 |
WO2017127565A1 (en) * | 2016-01-19 | 2017-07-27 | The Regents Of The University Of California | Methods for the treatment of danon disease and other disorders of autophagy |
-
2019
- 2019-06-07 CN CN201980038176.7A patent/CN112272705A/zh active Pending
- 2019-06-07 SG SG11202011061SA patent/SG11202011061SA/en unknown
- 2019-06-07 CA CA3100280A patent/CA3100280A1/en active Pending
- 2019-06-07 US US16/972,740 patent/US20210260215A1/en active Pending
- 2019-06-07 IL IL279225A patent/IL279225B1/en unknown
- 2019-06-07 MX MX2020013313A patent/MX2020013313A/es unknown
- 2019-06-07 WO PCT/US2019/036157 patent/WO2019237067A1/en unknown
- 2019-06-07 JP JP2020568431A patent/JP2021526818A/ja active Pending
- 2019-06-07 EP EP19815084.9A patent/EP3814512A4/en active Pending
- 2019-06-07 KR KR1020217000163A patent/KR20210018902A/ko unknown
- 2019-06-07 BR BR112020024935-1A patent/BR112020024935A2/pt unknown
- 2019-06-07 AU AU2019282822A patent/AU2019282822A1/en active Pending
-
2020
- 2020-12-07 CL CL2020003190A patent/CL2020003190A1/es unknown
- 2020-12-31 CO CONC2020/0016718A patent/CO2020016718A2/es unknown
-
2024
- 2024-04-08 JP JP2024062211A patent/JP2024097779A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016521708A (ja) * | 2013-06-07 | 2016-07-25 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 環状アデノシン一リン酸−インコンピテントアデニリルシクラーゼならびに心不全を処置するおよび心機能を増大させるための組成物および方法 |
WO2017127565A1 (en) * | 2016-01-19 | 2017-07-27 | The Regents Of The University Of California | Methods for the treatment of danon disease and other disorders of autophagy |
Non-Patent Citations (3)
Title |
---|
FRONTIERS IN MOLECULAR NEUROSCIENCE, 2015, VOL.8, ARTICLE 36, JPN6023021214, ISSN: 0005067120 * |
SCIENCE TRANSLATIONAL MEDICINE, 2011, VOL.3, NO.92, 92RA64, JPN6023021212, ISSN: 0005067118 * |
THE JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2003, VOL.125, NO.6, PP.1461-1469, JPN6023021213, ISSN: 0005067119 * |
Also Published As
Publication number | Publication date |
---|---|
CO2020016718A2 (es) | 2021-04-08 |
IL279225A (en) | 2021-01-31 |
CN112272705A (zh) | 2021-01-26 |
MX2020013313A (es) | 2021-02-22 |
EP3814512A1 (en) | 2021-05-05 |
SG11202011061SA (en) | 2020-12-30 |
EP3814512A4 (en) | 2022-03-09 |
KR20210018902A (ko) | 2021-02-18 |
IL279225B1 (en) | 2024-07-01 |
CA3100280A1 (en) | 2019-12-12 |
BR112020024935A2 (pt) | 2021-03-09 |
CL2020003190A1 (es) | 2021-04-30 |
US20210260215A1 (en) | 2021-08-26 |
JP2024097779A (ja) | 2024-07-19 |
WO2019237067A1 (en) | 2019-12-12 |
AU2019282822A1 (en) | 2020-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2021526818A (ja) | 心筋症のためのaav心臓遺伝子治療 | |
US20220265858A1 (en) | Aav cardiac gene therapy for cardiomyopathy in humans | |
Byrne et al. | Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals | |
Fang et al. | Comparison of adeno-associated virus serotypes and delivery methods for cardiac gene transfer | |
AU2017371043B2 (en) | IL-1Ra cDNAs | |
CN114231532B (zh) | 在哺乳动物肌肉中特异性启动基因的启动子序列及其应用 | |
Pan et al. | Long-term robust myocardial transduction of the dog heart from a peripheral vein by adeno-associated virus serotype-8 | |
US20090105148A1 (en) | Compositions and methods for treating myocardial infarction | |
US20240139343A1 (en) | Increased packaging efficiency of vector for cardiac gene therapy | |
EA046532B1 (ru) | Генная терапия сердца с помощью aav при кардиомиопатии | |
JP2023537903A (ja) | リソソーム障害に対する遺伝子療法 | |
EA046740B1 (ru) | Генная терапия сердца с применением aav для кардиомиопатии у людей | |
KR20240114769A (ko) | 증진된 발현을 위해 선택된 코작 서열을 포함하는 조성물 | |
WO2023108157A1 (en) | Methods and compositions for treating mybpc3 related hypertrophic cardiomyopathy with a viral vector | |
WO2023108130A2 (en) | Compositions comprising kozak sequences selected for enhanced expression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220607 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220607 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230526 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230825 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231026 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20231208 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240408 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20240408 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20240410 |